Aktis Oncology, Inc. (AKTS)

US — Healthcare Sector

Peers:

Automate Your Wheel Strategy on AKTS

With Tiblio's Option Bot, you can configure your own wheel strategy including AKTS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol AKTS
Rev/Share 0.0
Book/Share 0.0
PB 0.0
Debt/Equity -0.1368
CurrentRatio 15.9841
ROIC -0.1686

MktCap 942774890.0
FreeCF/Share 0.0
PFCF 79.2248
PE 0.0
Debt/Assets 0.0368
DivYield 0
ROE 0.6559

Rating D+
Score 1
Recommendation Strong Sell
P/E Score 1
DCF Score 1
P/B Score 1
D/E Score 1

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
Initiation	AKTS	BofA Securities	--	Buy	--	$34	Feb. 3, 2026
Initiation	AKTS	JP Morgan	--	Overweight	--	$30	Feb. 3, 2026
Initiation	AKTS	Leerink Partners	--	Outperform	--	$31	Feb. 3, 2026
Initiation	AKTS	TD Cowen	--	Buy	--	--	Feb. 3, 2026

News

Huge Insider Buying Now at This Insurance Giant and 2 Biotechs

AKTS, ALMS, WRB
Published: January 19, 2026 by: 24/7 Wall Street
Sentiment: Positive

In the past week, a beneficial owner has continued to build a stake in insurance giant W.R.

image for news Huge Insider Buying Now at This Insurance Giant and 2 Biotechs

A Fresh IPO That Long-Term Investors Shouldn't Ignore

AKTS
Published: January 14, 2026 by: MarketBeat
Sentiment: Neutral

For speculative investors, the start of each year is always a good time to revisit an initial public offering (IPO) calendar. Almost every week, companies go public, with a handful of them offering considerable short-term upside potential.

image for news A Fresh IPO That Long-Term Investors Shouldn't Ignore

Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets

AKTS, LLY
Published: January 09, 2026 by: Business Wire
Sentiment: Neutral

LOS ANGELES & BOSTON--(BUSINESS WIRE)--Vida Ventures (“Vida”), a next-generation life sciences venture firm, today congratulates Aktis Oncology (Nasdaq: AKTS), a clinical-stage biotechnology company advancing a pipeline of alpha-emitting radiopharmaceuticals for the treatment of solid tumors. Aktis raised $318 million in its initial public offering, reflecting strong investor interest, its recently announced anchor investment by Eli Lilly and Company (NYSE: LLY), and pipeline momentum as the co.

image for news Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets

About Aktis Oncology, Inc. (AKTS)

IPO Date 2026-01-09
Website https://www.aktisoncology.com
Industry Biotechnology
CEO Matthew Roden
Employees None

Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatment of locally advanced or metastatic urothelial cancer. Its products include AKY-1189 to deliver a radioisotope to Nectin-4 expressing tumors for the treatment of metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and AKY-2519 to deliver radioisotope to B7-H3 CD276 expressing tumors targeting prostate, lung and other solid tumors. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is based in Boston, Massachusetts.